Points to consider for the reporting of variants of uncertain significance in germline genetic and genomic testing: A statement of the American College of Medical Genetics and Genomics (ACMG)

Genetics in Medicine

Jun 12, 2026
Manuscript

Chloe Mighton, Aya Abu-El-Haija, Vimla Aggarwal, Yassmine M.N. Akkari, Caroline Astbury, D. Hunter Best, Laura K. Conlin, Steven M. Harrison, Nan Jiang, Paul Kruszka, Dianalee McKnight, Tiffany T. Nguyen Dolphyn, Farid Barquet Ramos, Christie P. Thomas, Lora J.H. Bean, Heidi L. Rehm

Summary
We have outlined below a series of general recommendations for VUS reporting (Figure 3, Box 2) based on the most common germline genetic and genomic testing scenarios and assuming no subclasses of VUS are available. These recommendations refer to test results from any germline genetic or genomic testing platform, including but not limited to chromosomal microarray analysis (CMA), exome sequencing (ES), genome sequencing (GS), multigene panel testing, genotyping, optical genome mapping, and other technologies assessing germline genetic variation. These recommendations do not apply to G-banded karyotype analysis because formal pathogenicity classification is often not performed, and instead, an abnormal karyotype may include a recommendation to follow up with orthogonal tests that can provide more granular resolution. These general recommendations are then followed by additional considerations related to the use of VUS subclasses and exceptions to the general recommendations. It should be noted that although our survey was distributed globally, and all views were considered, the final recommendations summarized here fall within allowable regulations in the United States today and did not address existing policies or regulations in other countries that may hinder implementation. Furthermore, these recommendations apply to variants related to Mendelian diseases, with a range of penetrance, but do not apply to risk alleles.